Integra Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Integra Lifesciences (IART).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

3S.Buy

1Buy

6Hold

3Sell

Consensus RatingMarket Outperform# Analysts13Avg. Consensus PT$20Upside to Avg. PT+49.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	UBS	Patrick Wood	PT Cut	Neutral	$19→$14
Oct 26, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$15→$13
Oct 22, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$15→$14
Oct 22, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$15→$14
Oct 22, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$15→$13
Oct 22, 2026	Citizens	Daniel Stauder	PT Cut	Market Outperform	$25→$22
Oct 22, 2026	JP Morgan	Robbie Marcus	PT Cut	Underweight	$17→$14
Oct 14, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$19→$15
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$19→$15
Oct 5, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$18→$15
Jul 30, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$15→$18
Jul 28, 2026	UBS	Patrick Wood	Initiate	Neutral	$19
Jul 16, 2026	Truist Securities	Ravi Misra	PT Raise	Hold	$14→$19
Jul 9, 2026	BMO Capital	Vik Chopra	Initiate	Market Perform	$19
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$16→$19
May 28, 2026	Citigroup	Joanne Wuensch	Upgrade	Sell→Neutral	$11→$16
May 6, 2026	Citigroup	Joanne Wuensch	PT Raise	Sell	$9→$11
May 6, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$12→$15
Apr 15, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$13→$12
Apr 15, 2026	Argus Research	David Toung	Downgrade	Buy→Hold	—

Analyst Ratings News

PRO
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.

Benzinga Newsdesk

Integra Lifesciences Holdings Corp

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

People Also Watch

People Also Watch

Integra Lifesciences Holdings Corp

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PROTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

PROCitigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PROBMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PROWells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PROCitizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22